Download MendeleyDevelopment of a novel tricyclic class of potent and selective FIXa inhibitors.
Meng, D., Andre, P., Bateman, T.J., Berger, R., Chen, Y.H., Desai, K., Dewnani, S., Ellsworth, K., Feng, D., Geissler, W.M., Guo, L., Hruza, A., Jian, T., Li, H., Metzger, J., Parker, D.L., Reichert, P., Sherer, E.C., Smith, C.J., Sonatore, L.M., Tschirret-Guth, R., Wu, J., Xu, J., Zhang, T., Campeau, L.C., Orr, R., Poirier, M., McCabe-Dunn, J., Araki, K., Nishimura, T., Sakurada, I., Hirabayashi, T., Wood, H.B.(2015) Bioorg Med Chem Lett 25: 5437-5443
- PubMed: 26318999
- DOI: https://doi.org/10.1016/j.bmcl.2015.07.078
- Primary Citation of Related Structures:
5EGM - PubMed Abstract:
Using structure based drug design, a novel class of potent coagulation factor IXa (FIXa) inhibitors was designed and synthesized. High selectivity over FXa inhibition was achieved. Selected compounds were evaluated in rat IV/PO pharmacokinetic (PK) studies and demonstrated desirable oral PK profiles. Finally, the pharmacodynamics (PD) of this class of molecules were evaluated in thrombin generation assay (TGA) in Corn Trypsin Inhibitor (CTI) citrated human plasma and demonstrated characteristics of a FIXa inhibitor.
Organizational Affiliation:
Department of Discovery Chemistry, Merck Research Laboratories, Merck & Co., Inc., PO Box 2000, Rahway, NJ 07065, USA. Electronic address: dongfang-meng@merck.com.
